The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium

Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium

April 2, 2014 • By Kimberly Retzlaff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dairy is of interest because it shows promise for reducing urate levels. “The more dairy you eat, the less gout you have,” Dr. Pillinger said. “And that holds after you adjust for meat consumption. It looks like something or other in dairy products drives the kidneys to excrete more uric acid.”

You Might Also Like
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • ACR Releases Guidelines for Gout Management
  • Treatment, Management Options for Difficult-to-Control Gout
Explore This Issue
April 2014
Also By This Author
  • Paul Davis, MD, Steps Down as Editor-in-Chief of Clinical Rheumatology

The baseline plan for managing established gout also includes indications for urate lowering. One key with urate-lowering therapy is to “treat to target,” Dr. Pillinger said. “The minimum serum urate target is less than 6.0 mg/dL, and serum urate lowering below 5 mg/dL may be needed to improve gout signs and symptoms.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Use of an XOI, either allopurinol or febuxostat, is the recommended first-line therapy for urate lowering. An alternative first-line therapy, if at least one XOI is contraindicated or not tolerated, is the uricosuric probenecid. Probenecid is not considered a first-line therapy because it isn’t as effective as the XOIs, and there are limitations for using it, Dr. Pillinger noted.

“[Probenecid] doesn’t work well in people with any more than mild kidney disease because it relies on renal function to work,” Dr. Pillinger said. “Additionally, probenecid can raise the risk of kidney stones, particularly in patients with a history of them. Probenecid gets rid of urate by pushing it into the renal pelvis and into the urine,” he said. “You concentrate it in the kidney where it can precipitate. You have to drink a lot of water and may have to take medicine to keep the urine alkalotic.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Prophylaxis

It’s extremely important to initiate prophylaxis along with urate-lowering therapy, Dr. Pillinger said. The ACR recommends low-dose colchicine (0.5–0.6 qD or BID) or low-dose NSAIDs (e.g., naproxen 250 BID) for first-line therapies and prednisone equal to or less than 10 mg/day as a second-line therapy.

Another important recommendation is to periodically assess for gout activity (e.g., acute attacks, persistent tophi, persistent chronic synovitis) during treatment. Prophylaxis should be continued if any disease activity is still present.

“Don’t stop the prophylaxis until the risk of attacks has gone away, and that’s characterized by getting rid not only of hyperuricemia, but also of the attacks themselves, as well as visible tophi and occult urate deposits, and then giving time to allow the dust to settle,” Dr. Pillinger said. “This will be four to five months minimum, and the maximum could be several years. This a very important recommendation.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Kimberly J. Retzlaff is a medical journalist based in Denver.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Crystal Arthritis, Meeting Reports Tagged With: anti-inflammatory, crystal arthritis, Gout, patient care, rheumatologist, rheumatology symposium, TreatmentIssue: April 2014

You Might Also Like:
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • ACR Releases Guidelines for Gout Management
  • Treatment, Management Options for Difficult-to-Control Gout
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)